Technical Analysis for OXBDF - Oxford Biomedical Lt

Grade Last Price % Change Price Change
grade B 9.725 4.91% 0.4550
OXBDF closed up 4.91 percent on Monday, July 6, 2020, on 15 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical OXBDF trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Gapped Up Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness 4.91%
Oversold Stochastic Weakness 4.91%
Stochastic Buy Signal Bullish 5.71%
Lower Bollinger Band Walk Weakness 5.71%
Lower Bollinger Band Touch Weakness 5.71%
Older signals for OXBDF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development include OXB-102 that is in Phase I/IIa study preparation for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; and OXB-302, a gene-based cancer immunotherapy product that has completed pre-clinical development for use in the treatment of a range of cancers, as well as OXB-201 that has completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. It is also developing gene-based therapies, such as SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, which is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, and Immune Design. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Branches Of Biology Biopharmaceutical Life Sciences Biology Cancers Cell Therapy Immunotherapy Parkinson's Disease Gene Therapy Platform Technology Macular Degeneration Treatment Of Parkinson's Disease Central Nervous System Disorders Virotherapy Diabetic Retinopathy Medical Genetics Genetic Engineering Parkinson's Treatment Of A Range Of Cancers Cell Therapy Products Applied Genetics Treatment Of Various Cancers

Is OXBDF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 15.15
52 Week Low 5.0
Average Volume 3,889
200-Day Moving Average 8.6043
50-Day Moving Average 9.5325
20-Day Moving Average 9.8440
10-Day Moving Average 9.4005
Average True Range 0.3863
ADX 13.93
+DI 36.2547
-DI 31.2411
Chandelier Exit (Long, 3 ATRs ) 9.7411
Chandelier Exit (Short, 3 ATRs ) 9.9089
Upper Bollinger Band 10.9067
Lower Bollinger Band 8.7813
Percent B (%b) 0.44
BandWidth 21.5908
MACD Line -0.0845
MACD Signal Line 0.0132
MACD Histogram -0.0977
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.0175
Resistance 3 (R3) 10.0333 9.9517 9.9688
Resistance 2 (R2) 9.9517 9.8772 9.9438 9.9525
Resistance 1 (R1) 9.8383 9.8312 9.7975 9.8225 9.9362
Pivot Point 9.7567 9.7567 9.7363 9.7488 9.7567
Support 1 (S1) 9.6433 9.6822 9.6025 9.6275 9.5138
Support 2 (S2) 9.5617 9.6362 9.5538 9.4975
Support 3 (S3) 9.4483 9.5617 9.4813
Support 4 (S4) 9.4325